Abstract: Purpose/Background: It is unclear whether increasing the dose of varenicline beyond the standard dose of 2 mg/d would improve smoking abstinence.
and nicotine replacement therapy (OR,~1.7:1). 3 However, even with an effective treatment such as varenicline, 55% to 60% of individuals would still fail to achieve abstinence from smoking at the end of treatment. 4 Initial concerns that varenicline increases the risk of developing neuropsychiatric adverse effects have not been substantiated in retrospective 5 and prospective studies, [6] [7] [8] further confirmed in the recently published EAGLES study, the largest (n = 8000) prospective placebo-controlled smoking-cessation study to date. 9 These studies have reassured patients and providers regarding the safety profile of varenicline and have encouraged researchers to explore novel ways of maximizing its effectiveness, including combining it with other medications 10 or using it in higher doses. 11 Varenicline, a novel and selective α4β2 nicotinic acetylcholine receptor partial agonist, was developed for smoking cessation and recommended to be used in divided dosage of 1 mg twice per day, to minimize adverse effects (eg, nausea), 12 although it is almost entirely excreted in the kidney with a halflife of 24 hours. 13 Craving reduction has been associated with increased varenicline concentrations presumably with higher receptor occupancy even in single-dose administration, 14 but no studies have examined that effect after weeks of higher dose intake. Patients who fail to quit smoking following medication treatment may be categorized as either (a) favorable responders (ie, those who had a favorable, albeit incomplete, treatment response by reducing their cigarettes per day [CPD] by half or more) but not quitting or (b) nonresponders (ie, those who failed to respond at all or have achieved a smaller reduction in CPD). 15 Two prior studies evaluated increased varenicline doses beyond 2 mg/d but produced conflicting results. The first was a retrospective case series study that showed that increasing varenicline from 2 mg/d to 3 mg/d resulted in a 50% increase in abstinence rate among 52 smokers who were "favorable responders" but had not quit after 8 weeks of 2 mg/d varenicline. 11 The second study was a randomized placebo-controlled trial involving 200 smokers initially treated for 2 weeks with 2 mg/d of varenicline, who were "nonresponders" because they did not quit and did not reduce smoking by half or more at 2 weeks. They were then randomized to varenicline 3 mg/d or varenicline 2 mg plus a placebo pill as a control. In this study, no significant improvement in smoking-abstinence rates was found by increasing the dose beyond 2 mg/d. 16 The equivocal findings of these 2 studies suggest that further research was needed to determine whether increasing varenicline dosage to 3 mg/d would convey further benefit and whether this increase would benefit a specific group of nonquitters (favorable responders). Here, we conducted a naturalistic and observational study of smokers enrolled in a comprehensive tobacco treatment program at a large cancer center, to evaluate whether increasing varenicline dosage improves abstinence rates among nonquitters who had an initial favorable response. We hypothesized that patients who had a favorable response (ie, reduced their CPD by half [50%] or more on 2 mg/d of varenicline) would have a higher smoking-cessation rate with an increase to 3 mg/d than would those who continued to receive 2 mg/d beyond the initial 6 weeks. We also examined adverse events and explored other baseline variables that can affect patients' smoking cessation as possible predictors of abstinence outcome.
METHODS

Participants
Of 2833 patients treated with varenicline, our analytic sample included cancer patients and survivors (n = 429) who participated in the Tobacco Treatment Program at The University of Texas MD Anderson Cancer Center (Houston, TX) from September 2006 through April 2015 who were initially prescribed 2 mg/d of varenicline (Fig. 1) . On the basis of previously observed clinical success in our practice, we began systematically offering to increase the patients' varenicline dose from 2 mg/d to 3 mg/d if they tolerated the medication and had an initial favorable response (reduced CPD by ≥50% from baseline) but were unable to achieve total abstinence. Based on patients' preference after offering them the option to increase to 3 mg/d, the varenicline dose was either increased to 3 mg/d (3-mg group, n = 73) or maintained at 2 mg/d (2-mg group, n = 356) for a minimum of an additional 4 weeks. Patients who chose to stay on 2 mg (eg, some felt they were making progress and want to continue on same dose; others wanted to make an extra behavioral effort and did not want to rely solely on the medication) received a 1-mg tablet twice per day. Patients who agreed to increase to 3 mg received 3 tablets per day (2 tablets of 1 mg in the morning and 1 tablet of 1 mg in the evening or vice versa, depending on patients' preference).
To reach our analytic sample of n = 429 (356 + 73), we started from a total of 2833 patients in our program who were prescribed 2 mg/d of varenicline. We excluded 1280 patients who took 2 mg/d of varenicline for less than 6 weeks. Of the remaining 1553 patients, 115 patients were prescribed 3 mg/d, and 1438 patients stayed on 2 mg/d. Among the 1438 patients who remained on 2 mg/d, 482 patients were excluded for taking varenicline for more than 1 episode of care; as such, there was a gap in their medication in between both episodes, which left 956 patients who were receiving their first treatment of 2 mg/d. We further excluded 91 patients because of lack of baseline assessment data from their initial visit. Of the remaining 865 patients (in the 2-mg group), 509 patients (approximately 60%) had quit smoking at 6 weeks, leaving 356 patients who did not quit but stayed on 2 mg/d, and they became our comparator sample. We retrospectively identified 115 patients who had agreed to increase their dose to 3 mg/d; of those, we excluded 34 patients because there was no confirmation of them effectively increasing their dose and 8 patients because they had quit smoking right before the increase to 3 mg (the reasons for their dose increase were high cravings and fear of relapse) or had taken 3 mg for less
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Varenicline 3-mg Improves Abstinence than 1 week, leaving 73 smokers at the 3-mg/d dose eligible for analysis ( Fig. 1) . Among all our patients, 43% did not have cancer, whereas the most common cancer diagnoses were lung and hematologic-oncologic ones. Note that this is a retrospective analysis of data collected from a comprehensive tobacco treatment program. The MD Anderson Institutional Review Board had approved a 15-year repository of clinical data to be collected through our program for quality improvement and future dissemination of pertinent findings. The requirement for written informed consent was waived owing to the program following standard clinical procedures; patients' verbal consent was obtained and documented in their medical record before increasing their dose to 3 mg/d.
Procedures
Patients in both the 2-and 3-mg groups were motivated to quit smoking and participated in 6 or more sessions (15-30 minutes each) of smoking-cessation counseling in addition to receiving varenicline. These treatments were free of charge to all patients. Most follow-up counseling sessions were conducted by telephone (approximately 90%). At baseline (an inperson visit consisting of the first consult at our program), we administered the following standardized questionnaires: Center for Epidemiologic Studies Depression Scale, 17 the Patient Health Questionnaire, 18 the Brief Sleep Scale, 19 the Fagerström Test for Nicotine Dependence, 20 the Wisconsin Smoking Withdrawal Scale, 21 and the Positive and Negative Affect Schedule. 22 Those were administered to screen for depression, anxiety, alcohol, insomnia, nicotine dependence, nicotine withdrawal, and negative affect, respectively. We also assessed motivation to quit on a 1-item Likert scale (Table 1) : "How motivated are you to quit smoking?" The baseline values of these assessments were used as covariates to calculate the propensity scores to match the 2 treatment groups, as described below.
We recorded the CPD at each session using the timeline follow-back method, 23 and in a small group (n = 11) who attended in-person sessions, we measured exhaled carbon monoxide (CO) levels. Further details about our treatment program are reported elsewhere. 24 In addition to total abstinence, reduction in CPD by 50% or more has been used as a criterion for treatment response in studies evaluating the importance of switching treatment approaches (ie, switch to other treatments including varenicline, nicotine replacement therapies, or bupropion). 15, 25 In this study, we used timeline follow-back method data to establish the 50% reduction in CPD as criterion for a favorable response. In addition, we were interested in the robust reduction in smoking to 5 cigarettes or less per day, especially among those who smoked more than 10 CPD at baseline, the latter being a possible easy measure of a "robust response" while on varenicline at 2 mg/d, which could be used as proxy or marker of a substantial benefit in increasing the varenicline dose further. *The standardized differences are reported as percentages; a difference of less than 10.0% indicates a relatively small imbalance. † Sample size for the 2-and 3-mg groups after matching, varied by imputed data set. The ranges of the sample size were 135 to 145 for the 2-mg group and 68 to 73 for the 3-mg group. 
Data Analysis
All data analyses were conducted using R statistical software (version 3.3.0; http://www.r-project.org/). Baseline group differences were identified using χ 2 analysis. The effect of treatment group on smoking abstinence was estimated using the cumulative incidence ratio or risk ratio (RR), along with ORs.
Propensity Score Matching
Given the quasi-experimental nature of the study and to account for possible differences in the baseline characteristics between the 2 groups, we used the propensity score-matching method. 26, 27 A propensity score is the probability that a patient will be assigned to the 3-mg/d group as opposed to the 2-mg/d group given each patient's measured characteristics. A matched set consists of a patient in the 3-mg/d group and at least 1 patient from the control group with similar propensity (probability) scores. The aim of this method is to approximate or simulate randomization by eliminating confounding due to individual differences. We matched 142 patients who were initially treated and continued on 2 mg/d (of the 356 described previously) with the 73 patients whose dose was increased to 3 mg/d.
The propensity score in this study was estimated using a multivariate logistic regression model, with varenicline dose per day as the dependent variable and the baseline characteristics outlined previously and in Table 1 as covariates. In the propensity scorematching procedure, we reached the best compromise of balance and sample size with a matching of 1:3 using a greedy nearestneighbor-matching algorithm with a caliper width equal to 0.2 of the SD of the logit of the propensity score. The greedy nearest-neighbor-matching algorithm selects a subject from the 3-mg/d group and then selects a subject from the 2-mg/d group whose propensity score is closest to that of the 3-mg/d subject. The caliper of 0.2 constraints the selection of the matched subject to be within 0.2 unit of the propensity score. We estimated both unadjusted and adjusted RRs using a logistic regression model and compared the average expected values for each patient as the varenicline dose was increased from 2 mg to 3 mg. After estimating the propensity score, we performed a series of matching algorithms to extract the optimal balanced sample. We used R package MatchIt 28 software to perform the propensity score matching and Zelig 29 software to estimate the parameters of the models (Fig. 2) .
Missing Data
Prior to running the propensity score analysis, we used multiple imputation to impute (substitute) missing values in the covariates and minimize potential bias due to missingness using the program Amelia II. 30 Multiple imputation is an analytical technique for missing data, which consists of 3 steps: (a) imputation of missing values for a predetermined number of data sets (in this article, we created 10 imputed sets), (b) separate analysis in each data set, and (c) pooling and averaging the results from each imputed set. In the final models of the matched samples, we also included all covariates to adjust for potential imbalance not eliminated from our matching procedure. Amelia II software uses expectation-maximization with a bootstrapping algorithm, which is well suited for multivariate analysis of categorical or mixed data. 31 Expectation-maximization is an iterative method to find the best solution by maximizing the likelihood of the data given the parameters. Each iteration of the expectationmaximization algorithm uses random sampling. The percentages of missing data for the covariates ranged from 2% to 32%. To evaluate the imputation results, we imputed 10 data sets and examined the imputation diagnostics. We then performed the propensity score-matching algorithm on each imputed data set separately. We proceeded by averaging the results using Rubin's 26 rules for combining results from multiple imputed data sets to account for the uncertainty of the logistic regression results produced from each imputed and matched data set and to derive point estimates and confidence intervals (CIs) for the parameters of interest.
Sensitivity Analysis
Because of the lack of random assignment between the 2 treatment groups, we used a sensitivity analysis to estimate the effect of possible confounding variables (eg, selection bias or placebo effect). 32 For this analysis, we assumed that an unobserved confounder (or several unobserved confounders) had an OR of 2 with smoking abstinence and an OR of 2 with exposure to 3 mg/d of varenicline, both considerably higher than most of the observed covariate effects shown in Table 1 .
We also considered different assumed prevalence levels of the unobserved covariate in the population ranging from 1% to 30%. Briefly, we used the associations between exposure to 3 mg/d of varenicline to the outcome and the unobserved confounder to estimate the bias factor, which we then used to obtain the estimate of the relationship between the outcome and the exposure, adjusted for both the observed and the unobserved covariates. 33 Decrease in CPD by ≥50% Versus ≤5 CPD Our data analyses seem to suggest that those who smoked more than 10 CPD at baseline and reduced to 5 CPD or fewer while on varenicline 2 mg/d had a particular advantage with the further increase in dose of varenicline. However, the numbers in each subgroup (Table 2 ) are too small to make firmer a conclusion; therefore, the decrease in CPD by 50% or more seems to be a simple and reasonable predictor of response to higher dose that clinicians could use to identify patients who may benefit from this strategy.
RESULTS
Baseline Characteristics
Before propensity score matching, our patients were highly dependent on nicotine, with a mean Fagerström Test for Nicotine Dependence score of 5.0 (Table 1) . Before the imputation and matching analysis, we found that at 3 months after the "increase or stay same" visit, 41 (11.5%) of 356 patients in the 2-mg group and 19 (26%) of 73 patients in the 3-mg group achieved 7-day point prevalence smoking abstinence (PPA). As shown in Table 3 (unadjusted model with no imputation), patients in the 3-mg group were significantly more likely to report 7-day PPA at the first outcome point (3 months) compared with those in the 2-mg group (χ 2 = 10.60; P < 0.001; RR, 2.3; 95% CI, 1.4-3.6). The difference remained significant regardless if the sample was adjusted, matched with imputation, or none of the above. Similar statistically significant effects were observed for 7-day PPA at 6 months' (P < 0.001; RR, 2.6; 95% CI, 1.6-3.9) and 9 months' follow-up (P < 0.001; RR, 2.2; 95% CI, 1.4-3.3). Table 1 shows the observed mean differences between the groups for each baseline characteristic before and after matching. The final matched 2-and 3-mg groups consisted of 142 patients and 72 patients, respectively (1 of the patients from the 3-mg group did not have a matching control), and the mean differences were reduced by this matching. The adjusted models with imputation and matching (Table 4) are the final models and are considered "doubly robust" to confounding because we preprocessed the data to match patients on the basis of covariates and because we controlled for covariates in the estimation of the final parameters. 28 After matching, all but 2 (Positive and Negative Affect Schedule-Positive Affect and Patient Health Questionnaire-Depression) of the standardized mean differences between the 2-and 3-mg groups were smaller than 0.10 (Table 1) , which has been recommended as a maximum limit of differences between 2 groups to be treated as equivalent. 34 
Selecting Case Controls Using Propensity Score Matching
Smoking Abstinence
We next compared the proportion of patients in each matched treatment group who had quit smoking at 3, 6, and 9 months. The RRs of efficacy varied from 2.1 to 2.9. The adjusted and unadjusted RRs (with 95% CIs) of achieving 7-day PPA are presented in Table 3 , showing that patients who received the 3-mg dose had a significantly higher probability of 7-day PPA in all models than did those who stayed on the 2-mg dose.
In the sensitivity analysis results (Table 5) , none of the CIs crossed 1.0, suggesting that the significant relationship between the 3-mg dose and smoking abstinence was not sensitive to an unobserved confounder, which was modeled as if associated with approximately 2-fold increase in being in the 3-mg group and 2-fold increase in smoking abstinence. We further examined (21) 16 (30) 0.001 43 (20) 17 (21) <0.001 13 (2) 16 (11) 0.816 33 (1) 20 (2) (18) 20 (38) 0.113 34 (16) 21.6 (27) 0.093 20 (3) 17 (12) 0.792 33 (1) 10 (1) 0.326 34 (15) 22 (26) the smoking-abstinence rates for the patients in the 3-and 2-mg groups categorized according to 2 parameters before increasing varenicline to 3 mg: (1) reduced smoking by 50% or more from baseline visit and/or (2) reduced CPD (≤5 CPD) after the initial 6 weeks of 2 mg/d. Those who met both criteria seem to have the most robust response by increasing to 3 mg/d; they would be patients who were smoking 10 CPD or more at baseline and reduced to 5 CPD or fewer while on 2 mg/d before the increase in dose (Table 2) . For patient convenience and to accommodate patients who must travel some distance to return to MD Anderson, we conduct the majority (90%) of our counseling follow-up sessions over the phone. As such, there is no opportunity to conduct an expired CO assessment on these visits. However, we do measure exhaled CO levels for those patients who attended in-person follow-up visits. In this sample, we identified 11 patients attending an in-person follow-up: 4 reported abstinence from smoking, and all had CO levels of less than 2 ppm (≤4 ppm is the cutoff for abstinence), indicating 100% congruence between the self-report of smoking abstinence and the CO levels. Furthermore, most of the 7 patients who reported that they had not quit smoking had CO levels that were substantially higher than 4 ppm. Although this is a small number of the sample, the high congruence is consistent with the accuracy in self-report on tobacco use in the literature, 35, 36 and it does provide confidence in the veracity of self-reported abstinence of our patients.
Adverse Events
At least 1 adverse event was reported by 146 patients (34%) in both groups (total sample of 429 patients). No significant difference in the presence or absence of at least 1 adverse effect was found between the 2-and 3-mg groups. Specifically, 23 patients (31.5%) in the 3-mg group experienced an adverse event compared with 123 patients in the 2-mg group (34.5%; χ 2 = 0.25; P = 0.617). We also compared the number of adverse events for only patients who had experienced 1 or more adverse events in both groups (2 and 3 mg/d). The mean number of adverse effects was 2.2 (SD, 1.9) for the 2-mg group and was 3.2 (SD, 3.3) for the 3-mg group; however, this difference was not statistically significant (P = 0.062). No severe or serious adverse events were reported; almost all the adverse events were mild (or grade I), except few that were moderate (grade II). Those grade II were 4 occasions (3-mg group) and 2 occasions (2-mg group) of nausea, as well as 4 occasions of insomnia/vivid dreams in each of the 2 groups. The most frequently reported adverse events in our study were nausea, abnormal dreaming, insomnia, and headache, which are the most frequent varenicline-related adverse events reported in placebo-controlled trials.
1,2
Sensitivity Analysis
We examined the sensitivity of our results to unobserved confounding variables, as defined previously, which may have determined selection into the 3-mg group versus the 2-mg group. The results in Table 4 show that patients in the 3-mg group had an OR of 2.67 (95% CI, 1.06-6.7) of 7-day PPA at 3 months relative to patients in the 2-mg group. Similarly, the ORs of 7-day PPA were 2.96 at 6 months (95% CI, 1.23-7.12) and 3.24 at 9 months (95% CI, 1.3-3.9) for patients in the 3-mg group compared with the 2-mg group. Our sensitivity analyses indicate that the effect of 3 mg of varenicline on smoking abstinence is robust and is not the result of unobserved confounding variables.
DISCUSSION
Our data support the hypothesis that increasing the dose of varenicline to 3 mg/d is associated with significant increase in 7-day PP abstinence rates. This benefit was observed among patients who reduce their smoking (≥50%) but fail to quit following an initial 6 weeks of varenicline at 2 mg/d and later increased to 3 mg/d. The impetus for trying a higher dose is to enhance cessation rates among those who fail to quit after an initial treatment exposure before they get discouraged and may give up on trying to quit. Therefore, in the program, we have used innovative techniques, such as combining medications or increasing medication dose beyond the maximum recommended dose (as in this sample), to enhance the treatment effect. 24 This favorable outcome was achieved with a relatively small increase in varenicline (30% difference in the daily dose), which suggests that a subgroup of patients may need a higher dose than the 2-mg/d dose to achieve total abstinence.
We found no significant differences in adverse events, by treatment group. This was probably due to the prolonged habituation period of 6 weeks on the 2-mg dose (ie, most adverse events likely occurred early while receiving the 2 mg/d, and those who did not tolerate varenicline would have stopped taking it). Therefore, a tailored increase in varenicline dosage among people who initially tolerated it can lead to an increased efficacy (abstinence from smoking) with no increase in adverse events.
A possible limitation is that the improved 7-day PPA rate in the 3-mg group could be attributed to a higher motivation to quit because these patients agreed to try this dose. However, we did assess motivation to quit at baseline, and no differences were found between the 2 groups. Another possible explanation is expectancy or "placebo effect," as patients in the 3-mg group took 3 tablets per day instead of 2 tablets and knew that they were taking a higher dose compared with the patients in the 2-mg group. Therefore, although the strength of this study is the real-world effectiveness in a natural setting, on the flip side of that is its major limitation as being a nonrandomized and open-label design, which could have resulted in a selection bias for patients in the 3-mg group. We tried to mitigate this possible bias by conducting a sensitivity analysis 32 that assumed up to a 2-fold chance of an "unobserved covariate" between the 2 groups, such as a variable that we did not measure or account for (eg, placebo effect), yet our results did not change. Nevertheless, only a randomized controlled trial, using a placebo tablet versus varenicline as "add on," among those who have an initial favorable response can eliminate the possibility of a selection bias or a placebo effect.
In conclusion, increasing varenicline to 3 mg/d seems to improve 7-day PPA rates at 3, 6, and 9 months from the onset of the possible change of treatment among those who previously received a 2-mg dose for 6 weeks and who had reduced CPD by 50% or more. Furthermore, the increased dose of varenicline did not increase the incidence of adverse events and was found to be safe in our study.
